ALK and lung adenocarcinoma: Here, we report a case of prolonged tumor response to the combination of immunotherapy with chemotherapy in a non-smoking <i>BRAF</i> V600E NSCLC patient.<h4>Materials and methods</h4>We verify a co-expression of <i>BRAF</i> V600E mutation and PD-L1 high expression more than 50% on formalin-fixed paraffin-embedded tumor sample of a newly diagnosed lung adenocarcinoma patient by immunohistochemistry and <i>BRAF</i> V600E/<i>EGFR</i>/<i>ALK</i>/<i>ROS1</i> Mutations Detection Kit.